Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sipcam pacific australia pty. limited - simazine - suspension concentrate - simazine triazine active 500.0 g/l - herbicide - almond over 3 years old | apple | asparagus | canola(tt varieties only) - pre emergent | chickpea | citrus over 1 year old | cur - annual or wimmera ryegrass | annual or wimmera ryegrass - suppression | annual thistle | barley grass | barley grass - suppression | bindy-eye | black bindweed - suppression | brome grass | brome grass - suppression | capeweed | cereal - self-sown | charlock | chickweed | clover | corn gromwell, ironweed or sheepweed | creeping oxalis | deadnettle | dock | fat hen | fumitory | geranium | hedge or wild mustard | indian hedge mustard | ivy leaf speedwell | lesser swinecress or bittercress | london rocket | mustard | nettle | paterson's curse | potato or yellow weed | powell's amaranth or powell's slim | prickly lettuce | purple goosefoot | radish | redroot or redroot amaranth | redshank | redshank,slim or spleen amaranth | ryegrass - suppression | sand fescue | shepherd's purse | silvergrass - aristida contorta | silvergrass - vulpia spp. | soursob or oxalis | soursob or oxalis - suppression | sow or milk thistle | squirrel-tail fescue or silver grass | three cornered jack or doublegee | turnip | turnip weed |

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - phleum pratense, quantity: 75000 sq-t - tablet - excipient ingredients: gelatin; mannitol; sodium hydroxide; purified water - grazax is indicated for disease modifying treatment of grass pollen (phleum pratense or allergens cross reacting with p. pratense) induced allergic rhinitis with or without conjunctivitis in adults, adolescents and children above the age of 5 years.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ezetimibe, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; carmellose sodium; povidone; sodium lauryl sulfate; polysorbate 80; magnesium stearate - adults (greater than or equal to 18 years),primary hypercholesterolaemia,ezetimibe administered alone, or with an hmg-coa reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.,homozygous familial hypercholesterolaemia (hofh),ezetimibe, administered with a statin, is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).,homozygous sitosterolaemia (phytosterolaemia),ezetimibe is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolaemia.,prevention of cardiovascular disease,ezetimibe is indicated for administration in combination with the maximum tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties, clinical trials).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),ezetimibe co-administered with simvastatin (doses up to 40 mg) is indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate: ? patients not appropriately controlled with a statin or ezetimibe alone ? patients already treated with a statin and ezetimibe,homozygous familial hypercholesterolaemia (hofh),ezetimibe co-administered with simvastatin (doses up to 40 mg) is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis)

Australia - English - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - ivermectin, quantity: 10 mg/g - cream - excipient ingredients: glycerol; isopropyl palmitate; carbomer copolymer (type b); dimeticone 20; disodium edetate; citric acid monohydrate; cetyl alcohol; stearyl alcohol; ceteareth-20; sorbitan stearate; methyl hydroxybenzoate; propyl hydroxybenzoate; phenoxyethanol; propylene glycol; oleyl alcohol; sodium hydroxide; purified water - soolantra is indicated for the topical treatment of inflammatory lesions of rosacea (papulo-pustular) in adult patients 18 years and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - ciclesonide, quantity: 50 microgram/actuation - spray, nasal - excipient ingredients: potassium sorbate; hypromellose; purified water; microcrystalline cellulose; disodium edetate; carmellose sodium; hydrochloric acid; nitrogen - omnaris nasal spray is indicated for: the treatment of seasonal allergic rhinitis in adults and children 6 years of age and older; and for the treatment of perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluvoxamine maleate, quantity: 100 mg - tablet, film coated - excipient ingredients: titanium dioxide; mannitol; macrogol 8000; magnesium stearate; hyetellose; iron oxide red; iron oxide yellow; iron oxide black - indicated for the treatment of major depression in adults. indicated for the treatment of obsessive compulsive disorder in children aged 8 years of age and older, adolescents, and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluvoxamine maleate, quantity: 50 mg - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 8000; magnesium stearate; mannitol; hyetellose; iron oxide yellow - indicated for the treatment of major depression in adults. indicated for the treatment of obsessive compulsive disorder in children aged 8 years of age and older, adolescents, and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - simvastatin, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; ascorbic acid; citric acid monohydrate; magnesium stearate; lactose monohydrate; pregelatinised maize starch; butylated hydroxyanisole; titanium dioxide; hypromellose; hyprolose; purified talc; iron oxide red - simvastatin arw is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin arw, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin arw is indicated in patients at high risk of chd (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. simvastatin arw is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with simvastatin arw secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - simvastatin, quantity: 40 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; ascorbic acid; magnesium stearate; butylated hydroxyanisole; microcrystalline cellulose; lactose monohydrate; citric acid monohydrate; titanium dioxide; hypromellose; hyprolose; purified talc; iron oxide red - simvastatin arw is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin arw, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin arw is indicated in patients at high risk of chd (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. simvastatin arw is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with simvastatin arw secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - simvastatin, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; ascorbic acid; citric acid monohydrate; butylated hydroxyanisole; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; hyprolose; purified talc; iron oxide yellow; iron oxide red - simvastatin arw is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin arw, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin arw is indicated in patients at high risk of chd (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. simvastatin arw is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with simvastatin arw secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.